Prospective randomised clinical trial for the medication in Metabolic Bone Diseases after Gastrectomy

Prospective randomised clinical trial for the medication in Metabolic Bone Diseases after Gastrectomy - Prospective randomised clinical trial for the medication in Metabolic Bone Diseases after Gastrectomy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015517

Enrollment

500

Registered

2014-10-24

Start date

2014-03-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis after gastrectomy

Interventions

The Minodolon acid hydrate administrated group The eldecalcitol administrated group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients for gastric cancer patients, who was operated gastrectomy for over three years Performance status(0-2) the case that was provided of the agreement.

Exclusion criteria

Exclusion criteria: Patients who cannot use Minodronic acid hydrate

Design outcomes

Primary

Measure	Time frame
Bone mineral density (BMD) of the lumber spine	—

Secondary

Measure	Time frame
Bone mineral density (BMD) of the proximal thighbone adverse event The ratio of the patients who completed the treatment bone metabolism marker(BAP NTX)	—

Countries

Japan

Contacts

Public ContactTakahashi Tsuyoshi

Osaka university graduate school of medicine Department of Gastroenterological Surgery

ttakahashi2@gesurg.med.osaka-u..ac.jp+81-6-6879-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026